Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study

by Latysheva, N , Cevoli, S , Sacco, S , Baraldi, C , Grazzi, L , Filatova, E , Russo, M , Ruscheweyh, R , Gryglas-Dworak, A , Frattale, I , Russo, A , Santoro, A , Martelletti, P , Alpuente, A , Ornello, R , Lambru, G , Kamm, K , Colombo, B , Negro, A , Silvestro, M , Straburzynski, M , Torelli, P , Pozo-Rosich, P , Guerzoni, S , Butera, C , Vernieri, F , Andreou, A. P , Altamura, Claudia , Miscio, A. M , Brunelli, N , Filippi, M , Ahmed, F

in Botulinum toxin type A / Geriatrics / Headache / Migraine / Neurology / Preventive medicine

2023

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study

in Botulinum toxin type A / Geriatrics / Headache / Migraine / Neurology / Preventive medicine

2023

Confirm

Do you wish to request the book?

OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study

in Botulinum toxin type A / Geriatrics / Headache / Migraine / Neurology / Preventive medicine

2023

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study

Latysheva, N,

Cevoli, S,

Sacco, S,

Baraldi, C,

Grazzi, L,

Filatova, E,

Russo, M,

Ruscheweyh, R,

Gryglas-Dworak, A,

Frattale, I,

Russo, A,

Santoro, A,

Martelletti, P,

Alpuente, A,

Ornello, R,

Lambru, G,

Kamm, K,

Colombo, B,

Negro, A,

Silvestro, M,

Straburzynski, M,

Torelli, P,

Pozo-Rosich, P,

Guerzoni, S,

Butera, C,

Vernieri, F,

Andreou, A. P,

Altamura, Claudia,

Miscio, A. M,

Brunelli, N,

Filippi, M,

Ahmed, F

2023

Overview

IntroductionAlthough migraine prevalence decreases with aging, some older patients still suffer from chronic migraine (CM). This study aimed to investigate the outcome of OnabotulinumtoxinA (OBT-A) as preventative therapy in elderly CM patients.MethodsThis is a post hoc analysis of real-life prospectively collected data at 16 European headache centers on CM patients treated with OBT-A over the first three treatment cycles (i.e., Cy1-3). We defined: OLD patients aged ≥ 65 years and nonOLD those < 65-year-old. The primary endpoint was the changes in monthly headache days (MHDs) from baseline to Cy 1–3 in OLD compared with nonOLD participants. The secondary endpoints were the responder rate (RR) ≥ 50%, conversion to episodic migraine (EM) and the changes in days with acute medication use (DAMs).ResultsIn a cohort of 2831 CM patients, 235 were OLD (8.3%, 73.2% females, 69.6 years SD 4.7). MHDs decreased from baseline (24.8 SD 6.2) to Cy-1 (17.5 SD 9.1, p < 0.000001), from Cy-1 to Cy-2 (14.8 SD 9.2, p < 0.0001), and from Cy-2 to Cy-3 (11.9 SD 7.9, p = 0.001). DAMs progressively reduced from baseline (19.2 SD 9.8) to Cy-1 (11.9 SD 8.8, p < 0.00001), to Cy-2 (10.9 SD 8.6, p = 0.012), to Cy-3 (9.6 SD 7.4, p = 0.049). The 50%RR increased from 30.7% (Cy-1) to 34.5% (Cy-2), to 38.7% (Cy-3). The above outcome measures did not differ in OLD compared with nonOLD patients.ConclusionIn a population of elderly CM patients with a long history of migraine OBT-A provided a significant benefit, over the first three treatment cycles, as good as in non-old patients.

Share this book

Add to My Shelf

Publisher

Springer Nature B.V

Subject

Botulinum toxin type A

/ Preventive medicine